ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
STORM Therapeutics Selects Clinical Candidate Targeting METTL3
October 29, 2020STORM Therapeutics has announced STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies. The Company intends to submit an IND application in 2021. -
STORM Therapeutics’ METTL3 inhibitor moves closer to the clinic
October 22, 2020University of Cambridge spin-out company STORM Therapeutics has announced that it has selected a first-in-class METTL3 candidate for development towards first in human clinical studies.
Pharma Sources Insight January 2025
